Esperion Therapeutics, Inc. (NASDAQ:ESPR) Shares Bought by Headlands Technologies LLC

Headlands Technologies LLC increased its holdings in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 55.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 255,066 shares of the biopharmaceutical company’s stock after acquiring an additional 90,522 shares during the period. Headlands Technologies LLC owned approximately 0.13% of Esperion Therapeutics worth $561,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in ESPR. Public Employees Retirement System of Ohio acquired a new stake in shares of Esperion Therapeutics during the 3rd quarter worth about $606,000. Anson Funds Management LP acquired a new stake in shares of Esperion Therapeutics in the third quarter valued at about $540,000. Wellington Management Group LLP grew its position in Esperion Therapeutics by 66.8% in the third quarter. Wellington Management Group LLP now owns 602,936 shares of the biopharmaceutical company’s stock valued at $995,000 after acquiring an additional 241,512 shares in the last quarter. Barclays PLC lifted its holdings in Esperion Therapeutics by 99.6% in the 3rd quarter. Barclays PLC now owns 309,671 shares of the biopharmaceutical company’s stock worth $510,000 after buying an additional 154,509 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its stake in shares of Esperion Therapeutics by 152.7% in the third quarter. BNP Paribas Financial Markets now owns 123,333 shares of the biopharmaceutical company’s stock worth $203,000 after acquiring an additional 74,522 shares in the last quarter. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on ESPR. Needham & Company LLC reissued a “buy” rating and set a $6.00 target price on shares of Esperion Therapeutics in a report on Friday, December 13th. JMP Securities reiterated a “market outperform” rating and issued a $4.00 price objective (down from $7.00) on shares of Esperion Therapeutics in a research report on Tuesday, February 11th. Cantor Fitzgerald initiated coverage on shares of Esperion Therapeutics in a research report on Tuesday, December 17th. They issued an “overweight” rating and a $8.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of Esperion Therapeutics in a report on Thursday, March 20th. Finally, The Goldman Sachs Group initiated coverage on Esperion Therapeutics in a report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 price objective for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $6.75.

Esperion Therapeutics Price Performance

Esperion Therapeutics stock opened at $1.29 on Friday. Esperion Therapeutics, Inc. has a 12-month low of $1.28 and a 12-month high of $3.94. The stock has a market capitalization of $255.23 million, a PE ratio of -2.02 and a beta of 1.04. The firm has a 50 day simple moving average of $1.71 and a 200-day simple moving average of $2.05.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.